Standard‐dose adrenaline (SDA) showed no clear difference in favourable neurological outcomes compared with placebo (low certainty).
Standard‐dose adrenaline (SDA) probably leads to higher return of spontaneous circulation compared with placebo (moderate certainty).
It is very uncertain whether standard‐dose adrenaline (SDA) changes survival to hospital discharge compared with high‐dose adrenaline (HDA) (very low certainty).
It is very uncertain whether standard‐dose adrenaline (SDA) changes survival to hospital admission compared with high‐dose adrenaline (HDA) (very low certainty).
It is very uncertain whether standard‐dose adrenaline (SDA) changes favourable neurological outcomes compared with high‐dose adrenaline (HDA) (very low certainty).
It is very uncertain whether standard‐dose adrenaline (SDA) changes return of spontaneous circulation compared with high‐dose adrenaline (HDA) (very low certainty).
It is very uncertain whether standard‐dose adrenaline (SDA) changes survival to hospital discharge compared with vasopressin (very low certainty).
Quinidine showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
Disopyramide showed no clear difference in recurrence of atrial fibrillation compared with placebo or no treatment (low certainty).
It is very uncertain whether propafenone changes all‐cause mortality compared with placebo or no treatment (very low certainty).
Propafenone probably leads to higher withdrawals due to adverse effects compared with placebo or no treatment (moderate certainty).
It is very uncertain whether propafenone changes proarrhythmia compared with placebo or no treatment (very low certainty).
The review found no eligible studies for this question.
Propafenone probably leads to lower recurrence of atrial fibrillation compared with placebo or no treatment (moderate certainty).
The review found no eligible studies for this question.
Flecainide showed no clear difference in withdrawals due to adverse effects compared with placebo or no treatment (low certainty).
Flecainide probably leads to higher proarrhythmia compared with placebo or no treatment (moderate certainty).
Flecainide showed no clear difference in stroke compared with placebo or no treatment (low certainty).
Quinidine showed no clear difference in withdrawals due to adverse effects compared with placebo or no treatment (moderate certainty).
Flecainide leads to lower recurrence of atrial fibrillation compared with placebo or no treatment (high certainty).